American College of Toxicology 31st Annual Meeting

WHAT PROPERTIES AND WHAT MAGNITUDE CHANGE WILL LEAD TO CARDIAC MORBIDITY AND MORTALITY ... reviews the current thought process on nonclinical aspects of the NDA from an industry perspective and from within the Office of New Drugs (OND) under the Center for Drug Evaluation and Research (CDER) at the FDA. ... Germantown, MD 20874. 775.750.9021 ... ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download